1. Western University of Health Sciences, Graduate School of Biomedical Science, Pomona, CA, United States;
2. Department of Psychiatry Wright University Boonshoft School of Medicine, Dayton, OH, United States;
3. Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT, United StatesGenetics of Alcoholism; Neuropsychiatry and Genetics; Nutritional Genetics; Pharmacogenetics
Well-known American Scientist in Psychopharmacology and Psychiatric Genetics.
Distinguished Top Professional to be featured in the Wall Street Journal.
Editor -in-Chief of Current Psychopharmacology, Addiction Psychiatry, and Theranostic and Pharmacological Sciences.
Associate Editor for Frontiers in Psychiatry and Frontiers in Public Health
Regional Editor for Current Pharmaceutical & Biotechnology. Recipient of NIH grants and has been awarded Lifetime Achievements,
Distinguished Honorary Doctors of Humane Letters;
Life-time Honorary Professor at ELTE Eötvös Loránd University, Hungary
Distinguished Honorary Professor at Adelson School of Medicine, Ariel University, Israel.
Adjunct professor at Western University, University of Vermont, Wright School of Medicine
Executive Chairman and CEO of TranspliceGen Therapeutics, Inc.
Stanford university credited him as top 2% of the World Best scientist list (2023).
The International Research Awards on Neurology and Neuro Disorders awarded him the “Best Researcher Award 2023”.
Burning mouth syndrome (BMS) is a debilitating medical condition affecting many people worldwide. Its common features include a burning painful sensation in the mouth, often associated with dysgeusia and xerostomia, despite normal salivation. BMS is one of the most common medically unexplained oral symptoms/syndromes. Several pathophysiological correlates have been reported so far, from endocrinological changes to psychological and neurophysiological alterations; such as the structural and functional imbalances between the amygdala and orbital frontal cortex Some results suggest potential neuromarkers for the diagnosis and treatment of BMS. To date, no specific biomarkers have been sufficiently validated to accurately identify patients suffering BMS and to evaluate treatment response to its treatment. Drug therapy with alpha lipoic acid, clonazepam, capsaicin, and antidepressants may provide symptom relief. Psychotherapy may be helpful. Short term follow up data is promising, however, long term prognosis with treatment is lacking. BMS remains an important medical condition which often places a recognizable burden on the patient and health care system and requires appropriate recognition and treatment.
This special issue welcomes articles focusing on, but not limited, to the following topics:
- Novel markers, biomarkers and potential neuromarkers for the diagnosis and treatment of BMS.
- Clinical trials and case studies on BMS.
- Application of Artificial Intelligence for early diagnosis of BMS.
- Novel application of Bayesian optimizations and Bayesian simulation and other models in translational pharmacology.
- Orofacial Pain Management.
-Application of supplements, natural compounds and complementary/ancillary medicine.
- Development of efficient Bayesian and other spatial models for pharmacological data.
- Animal models in the study and treatment of BMS.
- Protocols, reviews, systematic reviews and meta-analyses, mechanistic papers.